| DB ID | MyCo_3215 |
| Title | (1,3)-β-D-Glucan-based empirical antifungal interruption in suspected invasive candidiasis: a randomized trial |
| Year | 2020 |
| PMID | 32891170 |
| Fungal Diseases involved | Candida infection |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | albicans |
| Organism | Candida albicans |
| Ethical Statement | According to Italian law, the protocol was approved by the Università Cattolica del Sacro Cuore Ethics Committee (approval number UCSC20980/16), and written informed consent was obtained from the patient or the legally authorized representative. The trial was registered on www.clinical- trials.gov (NCT03117439). |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Italy |
| Cohort | This open-label, double-arm, randomized controlled trial was conducted in the 18-bed general ICU and in the 13- bed surgical ICU of a 1500-bed tertiary teaching hospital in Rome, from July 1, 2016, to June 30, 2018. Here randomized 108 patients into the (1,3)-β-D-glucan (n = 53) and control (n = 55) groups. |
| Cohort No. | 108 |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | FDA Approved-Fungitell assay |
| ELISA kits | None |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA Approved-Fungitell assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
